Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaëlle Rhyner Agocs

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Revue Medicale Suisse|September 10, 2019
[Immunotherapy: also in elderly patients ?]Gaëlle Rhyner Agocs, Vérène Dougoud-Chauvin, Daniel Betticher
Revue Medicale Suisse|October 24, 2024
[Malignant hypercalcemia]Dorian Garin, Inès Tornare, Gaëlle Rhyner Agocs, et al.
Journal of Personalized Medicine|August 27, 2021
LAG-3 Expression Predicts Outcome in Stage II Colon CancerGaëlle Rhyner Agocs, Naziheh Assarzadegan, Richard Kirsch, et al.
Cancers|May 25, 2024
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic RecoveryJulian Mehl, Dilara Akhoundova, Ulrike Bacher, et al.
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Revue Medicale Suisse|September 10, 2019
[Immunotherapy: also in elderly patients ?]Gaëlle Rhyner Agocs, Vérène Dougoud-Chauvin, Daniel Betticher
Revue Medicale Suisse|October 24, 2024
[Malignant hypercalcemia]Dorian Garin, Inès Tornare, Gaëlle Rhyner Agocs, et al.
Journal of Personalized Medicine|August 27, 2021
LAG-3 Expression Predicts Outcome in Stage II Colon CancerGaëlle Rhyner Agocs, Naziheh Assarzadegan, Richard Kirsch, et al.
Cancers|May 25, 2024
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic RecoveryJulian Mehl, Dilara Akhoundova, Ulrike Bacher, et al.
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
Pageof 1